-2%
- Maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)
- Maintenance treatment of asthma in patients aged 18 years and older
- Limitation of use:
- Not indicated for the relief of acute bronchospasm
Use this medicine only as directed by a registered physician.
This capsule is an inhalation powder formulated for oral inhalation, delivering a combination of:
- Fluticasone furoate (Inhaled Corticosteroid – ICS)
- Umeclidinium (Long-acting muscarinic antagonist – LAMA)
- Vilanterol (Long-acting beta₂-agonist – LABA)
The pharmacological effects of beta₂-agonists such as vilanterol are partly due to stimulation of intracellular adenyl cyclase, which converts adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). Increased cAMP levels lead to relaxation of bronchial smooth muscle and inhibition of the release of inflammatory mediators, particularly from mast cells.
The exact mechanism by which fluticasone furoate improves COPD and asthma symptoms is not fully understood. Inflammation plays a central role in the pathogenesis of both diseases. Corticosteroids exert anti-inflammatory effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and inflammatory mediators (e.g., histamine, leukotrienes, cytokines).
Umeclidinium is a long-acting muscarinic antagonist with similar affinity for muscarinic receptor subtypes M₁–M₅. In the airways, it inhibits M₃ receptors on smooth muscle, leading to bronchodilation.